Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Yahoo! Finance
to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the 41 participants dosed as of March 18, 2026 - - Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 - Friedreich's Ataxia (SGT-212): First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events - CPVT (SGT-501): Clinical sites activated for Phase 1b ARTEMIS first-in-human clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT); first participant dosing expected in Q2 2026 - Strong Capital Position: Cash, cash equivalents and available-for-sale securities of $187.9 million at December 31, 2025; in March 2026, the Company completed a $240 million private placement; the Company
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences (SLDB) is now covered by Guggenheim. They set a "buy" rating and a $26.00 price target on the stock.MarketBeat
- Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.MarketBeat
- Solid Biosciences (SLDB) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.MarketBeat
- Solid Biosciences GAAP EPS of -$0.53 misses by $0.02 [Seeking Alpha]Seeking Alpha
- Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire
SLDB
Earnings
- 3/19/26 - Miss
SLDB
Sec Filings
- 3/19/26 - Form S-3
- 3/19/26 - Form S-3
- 3/19/26 - Form S-8
- SLDB's page on the SEC website